Hardik Shah
2026.06.03 12:35

๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $Tempus AI(TEM.US) Tempus AI, Yale, and MSK Launch Open-Source Digital Pathology Consortium

๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:

โžค Tempus AI, ๐˜๐š๐ฅ๐ž ๐๐ž๐ฐ ๐‡๐š๐ฏ๐ž๐ง and ๐Œ๐’๐Š launch the IMS Consortium.

โžค Initiative aims to accelerate ๐๐ข๐ ๐ข๐ญ๐š๐ฅ ๐ฉ๐š๐ญ๐ก๐จ๐ฅ๐จ๐ ๐ฒ standardization and adoption.

โžค Tempus will open source the ๐๐š๐ข๐ ๐ž ๐ˆ๐Œ๐’ platform and key modules.

โžค Platform includes slide viewing, case management, and ๐€๐ˆ ๐จ๐ซ๐œ๐ก๐ž๐ฌ๐ญ๐ซ๐š๐ญ๐ข๐จ๐ง tools.

โžค Consortium seeks to build an open, interoperable digital pathology ecosystem.

โžค Focus includes AI-powered diagnostics, biomarker discovery, and workflow efficiency.

โžค Additional academic and industry members are expected to join over time.

๐Ÿ’ฌ ๐„๐ฑ๐ฉ๐ž๐ซ๐ญ ๐’๐ญ๐š๐ญ๐ž๐ฆ๐ž๐ง๐ญ:

โ€œPathology is entering a transformative new era,โ€ said Razik Yousfi, SVP and GM of AI Products at Tempus.

โ€œAdvances in deep learning and AI foundation models are enabling digital pathology to generate powerful insights directly from whole slide images, from cancer detection to molecular profiling. As demand for diagnostic and biomarker testing continues to rise, digital pathology offers a unique opportunity to enhance patient care by optimizing tissue utilization, uncovering actionable biomarkers, and improving laboratory workflows. We are excited to collaborate with YNHH and MSK to help bring the full potential of digital pathology into clinical practice.โ€

โ€œDigital pathology is transforming how we deliver diagnostics, advance translational research, and integrate AI into clinical care,โ€ said Chen Liu, MD, PhD, Chief of Pathology at YNHH.

โ€œWe are excited to join the Tempus IMS Consortium as a founding member and collaborate with leading academic and industry partners to help build an open, scalable, and interoperable digital pathology ecosystem. Open innovation and shared standards will be essential to accelerating adoption, improving workflow efficiency, and enhancing patient care.โ€

"Digital pathology lacks opensource and openaccess clinical-grade solutions for on-prem/cloud slide viewing, case management, and AI deployment," said Saad Nadeem, PhD, Associate Attending Computer Scientist at MSK.

"This open source IMS initiative is an important first step, providing opportunities for companies/institutions to develop, deploy, validate, monitor, and disseminate AI solutions with standardized workflows. Building on MSK's longstanding commitment and leadership in digital pathology, we look forward to working with our IMS Consortium partners to democratize access to digital pathology worldwide."

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.